Coronary artery disease (CAD) can reduce people’s life expectancy. However, this depends on various factors, including the severity of the condition, treatment efficacy, and whether the person has ...

The field of coronary artery disease saw its share of negative trials in 2024, but also got new guidelines, and a truce between interventionalists and surgeons. One long-awaited trial stood out: ...

In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. In a bid to address the persistent threat of coronary artery disease ...

A prospective, non-inferiority, randomised controlled TCW trial at 18 tertiary centres (2018-2023). Patients (n = 172) had severe aortic stenosis and complex coronary artery disease. They were ...

SpectraWAVE makes technologies to help diagnose and guide treatment decisions for coronary artery disease.

A noninvasive AI tool may be able to predict potential cardiovascular events in patients with suspected stable coronary ...

Both overweight and obesity can increase the risk of developing coronary artery disease. Maintaining a healthy diet and a moderate weight can help decrease the chance of this and other heart ...

Philips announced that it agreed to acquire SpectraWave, a developer of Enhanced Vascular Imaging (EVI) for coronary arteries ...

Philips and SpectraWAVE logos. December 15, 2025. Acquisition of SpectraWAVE’s next-generation technologies including ...